loading
Precedente Chiudi:
$4.51
Aprire:
$4.6
Volume 24 ore:
123.72K
Relative Volume:
0.12
Capitalizzazione di mercato:
$244.21M
Reddito:
$124.00K
Utile/perdita netta:
$-49.99M
Rapporto P/E:
-2.7718
EPS:
-1.69
Flusso di cassa netto:
$-31.03M
1 W Prestazione:
-5.05%
1M Prestazione:
-41.69%
6M Prestazione:
-17.25%
1 anno Prestazione:
-15.16%
Intervallo 1D:
Value
$4.60
$4.85
Intervallo di 1 settimana:
Value
$4.41
$4.93
Portata 52W:
Value
$3.785
$14.60

Candel Therapeutics Inc Stock (CADL) Company Profile

Name
Nome
Candel Therapeutics Inc
Name
Telefono
617-916-5445
Name
Indirizzo
117 KENDRICK STREET, NEEDHAM
Name
Dipendente
38
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
CADL's Discussions on Twitter

Confronta CADL con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
CADL
Candel Therapeutics Inc
4.685 244.21M 124.00K -49.99M -31.03M -1.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
490.08 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
577.44 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
599.32 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.66 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.34 26.16B 3.81B -644.79M -669.77M -6.24

Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-02-20 Iniziato Citigroup Buy
2025-02-19 Iniziato Canaccord Genuity Buy
2025-02-07 Iniziato BofA Securities Buy
2022-12-02 Iniziato H.C. Wainwright Buy
2021-11-19 Iniziato BMO Capital Markets Outperform
2021-08-23 Iniziato Credit Suisse Outperform
2021-08-23 Iniziato Jefferies Buy
2021-08-23 Iniziato UBS Buy
Mostra tutto

Candel Therapeutics Inc Borsa (CADL) Ultime notizie

pulisher
Apr 11, 2025

H.C. Wainwright maintains Buy on Candel Therapeutics stock By Investing.com - Investing.com Canada

Apr 11, 2025
pulisher
Apr 11, 2025

H.C. Wainwright maintains Buy on Candel Therapeutics stock - Investing.com Australia

Apr 11, 2025
pulisher
Apr 01, 2025

Candel Therapeutics Announces Publication of Phase 1b - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Candel Therapeutics announces publication of Phase 1b trial data on CAN-2409 - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Candel Therapeutics reveals new data showing better outcomes for glioma patients using CAN-2409 - Proactive financial news

Apr 01, 2025
pulisher
Apr 01, 2025

Candel reports positive phase 1b glioma trial results By Investing.com - Investing.com UK

Apr 01, 2025
pulisher
Mar 29, 2025

Candel Therapeutics reports breakthrough data for late-stage lung cancer – ICYMI - Proactive financial news

Mar 29, 2025
pulisher
Mar 27, 2025

Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients - AOL.com

Mar 27, 2025
pulisher
Mar 27, 2025

Candel Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:CADL - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Candel Therapeutics Shares Are Down Today: What's Going On? - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Candel Therapeutics shares positive survival data for investigational immunotherapy in NSCLC - Proactive financial news

Mar 27, 2025
pulisher
Mar 27, 2025

Candel Therapeutics Clinical Trial for CAN-2409 Demonstrates Promising Survival Extensions for NSCLC Patients Who Failed Previous Therapies - citybiz

Mar 27, 2025
pulisher
Mar 27, 2025

Candel Therapeutics Reports Positive Phase 2a Trial Results - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Trading (CADL) With Integrated Risk Controls - news.stocktradersdaily.com

Mar 27, 2025
pulisher
Mar 26, 2025

Candel Therapeutics Reports Final Phase 2a Survival Data for Lung Cancer Treatment - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

Candel Therapeutics Reports Both Prolonged Median Overall Survival And Long Tail Of Survival In Phase 2A Clinical Trial Of CAN-2409 In Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive To Immune Checkpoint Inhibitor (ICI) Treat - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

Candel Therapeutics reports positive survival data for CAN-2409 in advanced lung cancer trial - Proactive Investors

Mar 26, 2025
pulisher
Mar 26, 2025

Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatm - The Manila Times

Mar 26, 2025
pulisher
Mar 26, 2025

Breakthrough: Cancer Drug CAN-2409 Achieves 24.5-Month Survival in Advanced Lung Cancer Patients - Stock Titan

Mar 26, 2025
pulisher
Mar 26, 2025

Small cap wrap: Nano One Materials, EnWave, Summit Therapeutics... - Proactive financial news

Mar 26, 2025
pulisher
Mar 25, 2025

Bears are Losing Control Over Candel Therapeutics (CADL), Here's Why It's a 'Buy' Now - Zacks Investment Research

Mar 25, 2025
pulisher
Mar 21, 2025

CADLCandel Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan

Mar 21, 2025
pulisher
Mar 21, 2025

Candel therapeutics CEO sells $229,624 in stock By Investing.com - Investing.com Canada

Mar 21, 2025
pulisher
Mar 21, 2025

Insider Sell Alert: Paul Tak Sells 26,172 Shares of Candel Thera - GuruFocus

Mar 21, 2025
pulisher
Mar 20, 2025

Candel therapeutics chief scientific officer sells $281,672 in stock By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

Candel Therapeutics’ chief medical officer sells $396,995 in stock By Investing.com - Investing.com Canada

Mar 20, 2025
pulisher
Mar 20, 2025

Candel therapeutics CEO sells $229,624 in stock - Investing.com India

Mar 20, 2025
pulisher
Mar 20, 2025

Candel Therapeutics Executives Sell Shares Under Trading Plans - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

Candel Therapeutics’ chief medical officer sells $396,995 in stock - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

Small cap wrap: Santacruz Silver, GoviEx Uranium, Candel Therapeutics... - Proactive Investors

Mar 20, 2025
pulisher
Mar 20, 2025

Candel Therapeutics Partners With IDEA Pharma To Advance CAN-2409 Cancer Immunotherapy - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

Candel Therapeutics partners with IDEA Pharma on commercialization of CAN-2409 - Proactive Investors

Mar 20, 2025
pulisher
Mar 20, 2025

Candel Therapeutics Partners With IDEA Pharma for CAN-2409 Commercialization -March 20, 2025 at 08:29 am EDT - MarketScreener

Mar 20, 2025
pulisher
Mar 20, 2025

Candel Therapeutics and IDEA Pharma Announce Strategic - GlobeNewswire

Mar 20, 2025
pulisher
Mar 20, 2025

Breakthrough Prostate Cancer Drug Shows 30% Better Results as Candel Secures Key Partnership - Stock Titan

Mar 20, 2025
pulisher
Mar 19, 2025

Candel therapeutics CFO Charles Schoch sells $44,169 in stock By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Candel therapeutics CTO sells $275,947 worth of common stock By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Candel therapeutics CTO sells $275,947 worth of common stock - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Candel therapeutics CFO Charles Schoch sells $44,169 in stock - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Small cap wrap: Fineqia, Candel Therapeutics, Ocean Power Technologies, Protalix Biotherapeutics... - Proactive financial news

Mar 19, 2025
pulisher
Mar 18, 2025

Candel Therapeutics appoints cancer immunology expert to research advisory board - Proactive financial news

Mar 18, 2025
pulisher
Mar 18, 2025

Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board - The Manila Times

Mar 18, 2025
pulisher
Mar 18, 2025

Candel Therapeutics Appoints Renowned Pancreatic Cancer - GlobeNewswire

Mar 18, 2025
pulisher
Mar 18, 2025

Top Pancreatic Cancer Expert Joins Candel Therapeutics Following Promising Trial Results - StockTitan

Mar 18, 2025

Candel Therapeutics Inc Azioni (CADL) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Candel Therapeutics Inc Azioni (CADL) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Nichols William Garrett
Chief Medical Officer
Mar 18 '25
Sale
8.76
45,316
396,995
52,493
Barone Francesca
Chief Scientific Officer
Mar 18 '25
Option Exercise
1.55
18,000
27,900
128,673
Barone Francesca
Chief Scientific Officer
Mar 18 '25
Sale
8.76
32,146
281,673
96,527
Tak Paul Peter
Chief Executive Officer
Mar 18 '25
Sale
8.77
25,772
226,023
226,140
Tak Paul Peter
Chief Executive Officer
Mar 19 '25
Sale
9.00
400
3,601
225,740
Tyagarajan Seshu
Chief Technology Officer
Mar 17 '25
Sale
8.82
31,278
275,947
85,512
Schoch Charles
See Remarks
Mar 17 '25
Sale
8.83
5,000
44,169
38,038
$19.80
price down icon 1.75%
$70.30
price up icon 2.22%
$32.51
price up icon 0.87%
$26.24
price up icon 1.84%
$102.53
price down icon 0.01%
biotechnology ONC
$248.35
price up icon 8.46%
Capitalizzazione:     |  Volume (24 ore):